☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Myelodysplastic Syndrome
Gilead's Magrolimab Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndrome
September 16, 2020
Gilead to Acquire Forty Seven for $4.9B
March 2, 2020
Agios' Tibsovo (ivosidenib) Receives the US FDA's Breakthrough Therapy Designation for Patients with Relapsed or Refractory Myelod...
December 16, 2019
Load more...
Back to Home